Cargando…
Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease
BACKGROUND: Hand-foot-and-mouth disease (HFMD) is caused mainly by the human enterovirus type 71 (HEV71) and the Coxsackievirus A group type 16 (CVA16). Large outbreaks of disease have occurred frequently in the Asia-Pacific region. Reliable methods are needed for diagnosis of HFMD in childen. IgM-c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296593/ https://www.ncbi.nlm.nih.gov/pubmed/22234169 http://dx.doi.org/10.1186/1743-422X-9-12 |
_version_ | 1782225754018283520 |
---|---|
author | Yu, Nan Guo, Min He, Si-Jie Pan, Yu-Xian Chen, Xin-Xin Ding, Xi-Xia Hao, Wei Wang, Ya-Di Ge, Sheng-Xiang Xia, Ning-Shao Che, Xiao-Yan |
author_facet | Yu, Nan Guo, Min He, Si-Jie Pan, Yu-Xian Chen, Xin-Xin Ding, Xi-Xia Hao, Wei Wang, Ya-Di Ge, Sheng-Xiang Xia, Ning-Shao Che, Xiao-Yan |
author_sort | Yu, Nan |
collection | PubMed |
description | BACKGROUND: Hand-foot-and-mouth disease (HFMD) is caused mainly by the human enterovirus type 71 (HEV71) and the Coxsackievirus A group type 16 (CVA16). Large outbreaks of disease have occurred frequently in the Asia-Pacific region. Reliable methods are needed for diagnosis of HFMD in childen. IgM-capture ELISA, with its notable advantages of convenience and low cost, provides a potentially frontline assay. We aimed to evaluate the newly developed IgM-capture ELISAs for HEV71 and CVA16 in the diagnosis of HFMD, and to measure the kinetics of IgM over the course of HEV71 or CVA16 infections. RESULTS: We mapped, for the first time, the kinetics of IgM in HEV71 and CVA16 infection. HEV71- and CVA16-IgM were both detectable in some patients on day 1 of illness, and in 100% of patients by day 5 (HEV71) and day 8 (CVA16) respectively; both IgMs persisted for several weeks. The IgM detection rates were 90.2% (138 of 153 sera) and 68.0% (66 of 97 sera) for HEV71 and CVA16 infections, respectively, during the first 7 days of diseases. During the first 90 days after onset these values were 93.6% (233 of 249 sera) and 72.8% (91 of 125 sera) for HEV71 and CVA16 infections, respectively. Some cross-reactivity was observed between HEV71- and CVA16-IgM ELISAs. HEV71-IgM was positive in 38 of 122 (31.1%) CVA16 infections, 14 of 49 (28.6%) other enteroviral infections and 2 of 105 (1.9%) for other respiratory virus infected sera. Similarly, CVA16-IgM was apparently positive in 58 of 211 (27.5%) HEV71 infections, 16 of 48 (33.3%) other enterovirus infections and 3 of 105 (2.9%) other respiratory virus infected sera. Nevertheless, the ELISA yielded the higher OD(450 )value of main antibody than that of cross-reaction antibody, successfully identifying the enteroviral infection in 96.6% (HEV71) and 91.7% (CVA16) cases. When blood and rectal swabs were collected on the same day, the data showed that the agreement between IgM-capture ELISA and real-time RT-PCR in HEV71 was high (Kappa value = 0.729) while CVA16 somewhat lower (Kappa value = 0.300). CONCLUSIONS: HEV71- and CVA16-IgM ELISAs can be deployed successfully as a convenient and cost-effective diagnostic tool for HFMD in clinical laboratories. |
format | Online Article Text |
id | pubmed-3296593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32965932012-03-08 Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease Yu, Nan Guo, Min He, Si-Jie Pan, Yu-Xian Chen, Xin-Xin Ding, Xi-Xia Hao, Wei Wang, Ya-Di Ge, Sheng-Xiang Xia, Ning-Shao Che, Xiao-Yan Virol J Research BACKGROUND: Hand-foot-and-mouth disease (HFMD) is caused mainly by the human enterovirus type 71 (HEV71) and the Coxsackievirus A group type 16 (CVA16). Large outbreaks of disease have occurred frequently in the Asia-Pacific region. Reliable methods are needed for diagnosis of HFMD in childen. IgM-capture ELISA, with its notable advantages of convenience and low cost, provides a potentially frontline assay. We aimed to evaluate the newly developed IgM-capture ELISAs for HEV71 and CVA16 in the diagnosis of HFMD, and to measure the kinetics of IgM over the course of HEV71 or CVA16 infections. RESULTS: We mapped, for the first time, the kinetics of IgM in HEV71 and CVA16 infection. HEV71- and CVA16-IgM were both detectable in some patients on day 1 of illness, and in 100% of patients by day 5 (HEV71) and day 8 (CVA16) respectively; both IgMs persisted for several weeks. The IgM detection rates were 90.2% (138 of 153 sera) and 68.0% (66 of 97 sera) for HEV71 and CVA16 infections, respectively, during the first 7 days of diseases. During the first 90 days after onset these values were 93.6% (233 of 249 sera) and 72.8% (91 of 125 sera) for HEV71 and CVA16 infections, respectively. Some cross-reactivity was observed between HEV71- and CVA16-IgM ELISAs. HEV71-IgM was positive in 38 of 122 (31.1%) CVA16 infections, 14 of 49 (28.6%) other enteroviral infections and 2 of 105 (1.9%) for other respiratory virus infected sera. Similarly, CVA16-IgM was apparently positive in 58 of 211 (27.5%) HEV71 infections, 16 of 48 (33.3%) other enterovirus infections and 3 of 105 (2.9%) other respiratory virus infected sera. Nevertheless, the ELISA yielded the higher OD(450 )value of main antibody than that of cross-reaction antibody, successfully identifying the enteroviral infection in 96.6% (HEV71) and 91.7% (CVA16) cases. When blood and rectal swabs were collected on the same day, the data showed that the agreement between IgM-capture ELISA and real-time RT-PCR in HEV71 was high (Kappa value = 0.729) while CVA16 somewhat lower (Kappa value = 0.300). CONCLUSIONS: HEV71- and CVA16-IgM ELISAs can be deployed successfully as a convenient and cost-effective diagnostic tool for HFMD in clinical laboratories. BioMed Central 2012-01-11 /pmc/articles/PMC3296593/ /pubmed/22234169 http://dx.doi.org/10.1186/1743-422X-9-12 Text en Copyright ©2012 Yu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Yu, Nan Guo, Min He, Si-Jie Pan, Yu-Xian Chen, Xin-Xin Ding, Xi-Xia Hao, Wei Wang, Ya-Di Ge, Sheng-Xiang Xia, Ning-Shao Che, Xiao-Yan Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease |
title | Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease |
title_full | Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease |
title_fullStr | Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease |
title_full_unstemmed | Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease |
title_short | Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease |
title_sort | evaluation of human enterovirus 71 and coxsackievirus a16 specific immunoglobulin m antibodies for diagnosis of hand-foot-and-mouth disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296593/ https://www.ncbi.nlm.nih.gov/pubmed/22234169 http://dx.doi.org/10.1186/1743-422X-9-12 |
work_keys_str_mv | AT yunan evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT guomin evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT hesijie evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT panyuxian evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT chenxinxin evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT dingxixia evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT haowei evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT wangyadi evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT geshengxiang evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT xianingshao evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease AT chexiaoyan evaluationofhumanenterovirus71andcoxsackievirusa16specificimmunoglobulinmantibodiesfordiagnosisofhandfootandmouthdisease |